Biotechnology company Shire recently shared its findings that the Global Annual Bleed Rate (GABR) showed a bleeding incident occurs every 3 to 15 seconds in hemophilia patients worldwide.
In a release, Shire said it worked with World Federation of Hemophilia (WFH) and other leading hemophilia institutions to develop the GABR in order to identify areas worldwide that need improved diagnosis and care for patients. The WFH data also showed that of the approximately 180,000 people suffering from hemophilia A and B worldwide, only 25 percent have been diagnosed and receive proper care, and 8 percent are treated to prevent bleeds.
“As the global leader in hematology, we are committed to efforts, such as estimating the GABR, that improve our understanding of the global landscape for hemophilia and the true experience of those living with this debilitating bleeding disorder," Shire Global Head of Hematology Medical Affairs Dr. Leonard Valentino said in the release.
